FDA advisers reassert case against approval of Biogen’s Alzheimer’s drug
One of the most important decisions in the history of the Food and Drug Administration is quickly approaching. By ...
One of the most important decisions in the history of the Food and Drug Administration is quickly approaching. By ...
Humana and a group of live-in home health-care employees urged a Connecticut federal court to preliminarily approve a $17 ...
By Colin Gowdy March 23, 2021 11:53am A Lambton County-run long-term care home is planning to add 10-new dementia ...
With Eli Lilly’s donanemab and Biogen’s aducanumab jockeying for position in the race for key regulatory approvals, the so-called ...
TORONTO--(BUSINESS WIRE)--Bluma Wellness Inc. (the “Company” or “Bluma Wellness”) (CSE: BWEL.U) (OTCQX:BMWLF) is pleased to announce that shareholders of ...
A drug to halt the development of Alzheimer’s illness will doubtless be accepted throughout the subsequent three years, and ...
S | M | T | W | T | F | S |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | |||
5 | 6 | 7 | 8 | 9 | 10 | 11 |
12 | 13 | 14 | 15 | 16 | 17 | 18 |
19 | 20 | 21 | 22 | 23 | 24 | 25 |
26 | 27 | 28 |
© 2021 The Senior health Letter